Lipocine (LPCN) Reports Q3 Loss Per Share of $0.35

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/28/2026

1. ENPH
2. HOOD
3. BA
4. STX
5. NXPI
6. CSGP
7. LSTR
8. UPS
9. KIDS
10. V

Go back to Lipocine (LPCN) Reports Q3 Loss Per Share of $0.35

Lipocine Announces Financial and Operational Results for the Third Quarter of 2015

November 12, 2015 4:02 PM EST

SALT LAKE CITY, Nov. 12, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced financial results for the quarter ended September 30, 2015, as well as recent operational highlights.

Quarterly and Recent Highlights

Submitted a 505(b)(2) New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for LPCN 1021, an oral testosterone product candidate for... More